The effect of withdrawal of drugs treating intermittent claudication

David L Dawson, Christopher A. Demaioribus, Ryan T. Hagino, Jerry T. Light, Donald V. Bradley, Kathy E. Britt, Brandie E. Charles

Research output: Contribution to journalArticle

42 Citations (Scopus)

Abstract

Background: Pharmacologic treatment for intermittent claudication is a management option. This study evaluated the effect of withdrawal of drug therapies, cilostazol and pentoxifylline, on the walking ability of peripheral artery disease patients.Methods: Single-blind placebo crossover from a randomized, double-blind trial; 45 claudication patients received either cilostazol 100 mg orally twice daily (n = 16), pentoxifylline 400 mg orally three times daily (n = 13), or placebo (n = 16) for 24 weeks. After 24 weeks of double-blind therapy, treatment for all groups was placebo only, and follow-up continued through week 30. Treatment efficacy was established with treadmill testing.Results: Profile analysis demonstrated a highly significant loss of treatment benefit after crossover (P = 0.001) for cilostazol-treated patients, but no significant change after crossover was observed with pentoxifylline.Conclusions: Drug withdrawal worsened the walking of claudicants who had benefited from cilostazol therapy. This decline with crossover to placebo suggests that the initial improvement with cilostazol treatment was due to the drug's action. Withdrawal of pentoxifylline did not adversely affect walking. Copyright (C) 1999 Excerpta Medica Inc.

Original languageEnglish (US)
Pages (from-to)141-146
Number of pages6
JournalAmerican Journal of Surgery
Volume178
Issue number2
DOIs
StatePublished - Aug 1999
Externally publishedYes

Fingerprint

Intermittent Claudication
Pentoxifylline
Placebos
Pharmaceutical Preparations
Walking
Therapeutics
Single-Blind Method
Peripheral Arterial Disease
cilostazol
Drug Therapy

ASJC Scopus subject areas

  • Surgery

Cite this

Dawson, D. L., Demaioribus, C. A., Hagino, R. T., Light, J. T., Bradley, D. V., Britt, K. E., & Charles, B. E. (1999). The effect of withdrawal of drugs treating intermittent claudication. American Journal of Surgery, 178(2), 141-146. https://doi.org/10.1016/S0002-9610(99)00147-6

The effect of withdrawal of drugs treating intermittent claudication. / Dawson, David L; Demaioribus, Christopher A.; Hagino, Ryan T.; Light, Jerry T.; Bradley, Donald V.; Britt, Kathy E.; Charles, Brandie E.

In: American Journal of Surgery, Vol. 178, No. 2, 08.1999, p. 141-146.

Research output: Contribution to journalArticle

Dawson, DL, Demaioribus, CA, Hagino, RT, Light, JT, Bradley, DV, Britt, KE & Charles, BE 1999, 'The effect of withdrawal of drugs treating intermittent claudication', American Journal of Surgery, vol. 178, no. 2, pp. 141-146. https://doi.org/10.1016/S0002-9610(99)00147-6
Dawson, David L ; Demaioribus, Christopher A. ; Hagino, Ryan T. ; Light, Jerry T. ; Bradley, Donald V. ; Britt, Kathy E. ; Charles, Brandie E. / The effect of withdrawal of drugs treating intermittent claudication. In: American Journal of Surgery. 1999 ; Vol. 178, No. 2. pp. 141-146.
@article{b665fcd2cdff4636bdad5d770796b44d,
title = "The effect of withdrawal of drugs treating intermittent claudication",
abstract = "Background: Pharmacologic treatment for intermittent claudication is a management option. This study evaluated the effect of withdrawal of drug therapies, cilostazol and pentoxifylline, on the walking ability of peripheral artery disease patients.Methods: Single-blind placebo crossover from a randomized, double-blind trial; 45 claudication patients received either cilostazol 100 mg orally twice daily (n = 16), pentoxifylline 400 mg orally three times daily (n = 13), or placebo (n = 16) for 24 weeks. After 24 weeks of double-blind therapy, treatment for all groups was placebo only, and follow-up continued through week 30. Treatment efficacy was established with treadmill testing.Results: Profile analysis demonstrated a highly significant loss of treatment benefit after crossover (P = 0.001) for cilostazol-treated patients, but no significant change after crossover was observed with pentoxifylline.Conclusions: Drug withdrawal worsened the walking of claudicants who had benefited from cilostazol therapy. This decline with crossover to placebo suggests that the initial improvement with cilostazol treatment was due to the drug's action. Withdrawal of pentoxifylline did not adversely affect walking. Copyright (C) 1999 Excerpta Medica Inc.",
author = "Dawson, {David L} and Demaioribus, {Christopher A.} and Hagino, {Ryan T.} and Light, {Jerry T.} and Bradley, {Donald V.} and Britt, {Kathy E.} and Charles, {Brandie E.}",
year = "1999",
month = "8",
doi = "10.1016/S0002-9610(99)00147-6",
language = "English (US)",
volume = "178",
pages = "141--146",
journal = "American Journal of Surgery",
issn = "0002-9610",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - The effect of withdrawal of drugs treating intermittent claudication

AU - Dawson, David L

AU - Demaioribus, Christopher A.

AU - Hagino, Ryan T.

AU - Light, Jerry T.

AU - Bradley, Donald V.

AU - Britt, Kathy E.

AU - Charles, Brandie E.

PY - 1999/8

Y1 - 1999/8

N2 - Background: Pharmacologic treatment for intermittent claudication is a management option. This study evaluated the effect of withdrawal of drug therapies, cilostazol and pentoxifylline, on the walking ability of peripheral artery disease patients.Methods: Single-blind placebo crossover from a randomized, double-blind trial; 45 claudication patients received either cilostazol 100 mg orally twice daily (n = 16), pentoxifylline 400 mg orally three times daily (n = 13), or placebo (n = 16) for 24 weeks. After 24 weeks of double-blind therapy, treatment for all groups was placebo only, and follow-up continued through week 30. Treatment efficacy was established with treadmill testing.Results: Profile analysis demonstrated a highly significant loss of treatment benefit after crossover (P = 0.001) for cilostazol-treated patients, but no significant change after crossover was observed with pentoxifylline.Conclusions: Drug withdrawal worsened the walking of claudicants who had benefited from cilostazol therapy. This decline with crossover to placebo suggests that the initial improvement with cilostazol treatment was due to the drug's action. Withdrawal of pentoxifylline did not adversely affect walking. Copyright (C) 1999 Excerpta Medica Inc.

AB - Background: Pharmacologic treatment for intermittent claudication is a management option. This study evaluated the effect of withdrawal of drug therapies, cilostazol and pentoxifylline, on the walking ability of peripheral artery disease patients.Methods: Single-blind placebo crossover from a randomized, double-blind trial; 45 claudication patients received either cilostazol 100 mg orally twice daily (n = 16), pentoxifylline 400 mg orally three times daily (n = 13), or placebo (n = 16) for 24 weeks. After 24 weeks of double-blind therapy, treatment for all groups was placebo only, and follow-up continued through week 30. Treatment efficacy was established with treadmill testing.Results: Profile analysis demonstrated a highly significant loss of treatment benefit after crossover (P = 0.001) for cilostazol-treated patients, but no significant change after crossover was observed with pentoxifylline.Conclusions: Drug withdrawal worsened the walking of claudicants who had benefited from cilostazol therapy. This decline with crossover to placebo suggests that the initial improvement with cilostazol treatment was due to the drug's action. Withdrawal of pentoxifylline did not adversely affect walking. Copyright (C) 1999 Excerpta Medica Inc.

UR - http://www.scopus.com/inward/record.url?scp=0032869540&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032869540&partnerID=8YFLogxK

U2 - 10.1016/S0002-9610(99)00147-6

DO - 10.1016/S0002-9610(99)00147-6

M3 - Article

VL - 178

SP - 141

EP - 146

JO - American Journal of Surgery

JF - American Journal of Surgery

SN - 0002-9610

IS - 2

ER -